GlassScriptPhysician profile
Anya Veremakis
NPI 1194255828
$931.11
in general payments reported to CMS, 2019-2025
15 companies · $190 in 2025
The $190 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.26 · 2021: $50.99 · 2022: $353 · 2023: $241 · 2024: $84.80 · 2025: $190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $516.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $515.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $196.63 | 2022-2025 | Veozah |
| Organon LLC | $158.93 | 2021-2025 | Nexplanon |
| Hologic Sales and Service, LLC | $103.40 | 2022-2025 | Aptima, Thinprep 2000 Processor, Third Wave |
| Bayer Healthcare Pharmaceuticals INC. | $88.12 | 2022-2025 | |
| Abbvie INC. | $79.79 | 2022-2023 | Lo Loestrin Fe |
| Myovant Sciences INC. | $69.37 | 2021-2022 | |
| Exeltis, USA INC. | $51.23 | 2025 | Slynd |
| Sumitomo Pharma America, INC. | $50.84 | 2023-2025 | Myfembree |
| Coopersurgical, INC. | $43.99 | 2022-2025 | Endosee |
| Avion Pharmaceuticals | $35.99 | 2022-2023 | Balcoltra |
| Pfizer INC. | $15.76 | 2023 | |
| Meditrina | $11.69 | 2021 | |
| Therapeuticsmd, INC. | $11.31 | 2021 | |
| Olympus America INC. | $11.26 | 2019 | |
| Mayne Pharma Commercial LLC | $2.80 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anya Veremakis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.